EBS vs. XMMO

In the year-to-date period, EBS achieves a -40.90% return, which is significantly lower than XMMO's -2.51% return. Over the past 10 years, EBS has underperformed XMMO with an annualized return of -14.49%, while XMMO has yielded a comparatively higher 14.78% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Emergent BioSolutions Inc. (EBS) and Invesco S&P MidCap Momentum ETF (XMMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current EBS Sharpe Ratio is 0.24, which is comparable to the XMMO Sharpe Ratio of 0.19. The chart below compares the historical Sharpe Ratios of EBS and XMMO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

EBS has not paid dividends to shareholders, while XMMO's dividend yield for the trailing twelve months is around 0.51%.

The maximum EBS drawdown since its inception was -98.89%, which is greater than XMMO's maximum drawdown of -55.37%. Use the drawdown chart below to compare losses from any high point for EBS and XMMO. For additional features, visit the drawdowns tool.

Emergent BioSolutions Inc. (EBS) has a higher volatility of 37.43% compared to Invesco S&P MidCap Momentum ETF (XMMO) at 7.58%. This indicates that EBS's price experiences larger fluctuations and is considered to be riskier than XMMO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.